Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFevertree Regulatory News (FEVR)

Share Price Information for Fevertree (FEVR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,093.00
Bid: 1,093.00
Ask: 1,099.00
Change: 2.00 (0.18%)
Spread: 6.00 (0.549%)
Open: 1,080.00
High: 1,098.00
Low: 1,073.00
Prev. Close: 1,091.00
FEVR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FY23 pre-close trading update

25 Jan 2024 07:00

RNS Number : 8288A
Fevertree Drinks PLC
25 January 2024
 

Fever-Tree Drinks plc

FY23 pre-close trading update for the year ending 31st December 2023

 

Good operational progress has resulted in a doubling of EBITDA in the second half of the year despite a challenging trading environment.

Financial highlights

Revenue, £m

FY23

FY22

Change

Constant currency

UK

114.8

116.2

(1%)

 

US

117.0

95.6

22%

24%

  Europe (Fever-Tree brand revenue)

94.6

89.2

6%

4%

Europe total revenue*

105.4

101.0

4%

2%

ROW

27.2

31.5

(14%)

(10%)

Total

364.4

344.3

6%

6%

*includes GDP portfolio brand revenue

 

Fever-Tree delivered Group revenue growth of c.6% year-on-year to c.£364 million. Despite macroeconomic headwinds, the brand continues to make good progress, particularly in the US, and has delivered market share growth across our key markets. The Group expects to deliver Adjusted EBITDA for the full year of c.£30 million, within our guidance range. This means the Group doubled EBITDA in the second half of the year following significant progress in driving operational efficiencies and offsetting material inflationary cost pressures, and will continue to deliver significant margin improvement in 2024.

UK - Continued share gains

· Total UK revenue was ahead of guidance reflecting good trading in Q4, particularly in the On-Trade.

· In the Off-Trade, the brand delivered notable growth in our Gingers, Flavoured Sodas, and Adult Soft range, as well as a strong start for our new cocktail mixers, whilst in the On-Trade, despite the continued pressure on the cost of living, the brand ended the year with its strongest ever value share[1].

· The increasing diversification of the portfolio has ensured the brand remains the clear leader of the total UK mixer category[2] and best placed to capture gains as sentiment continues to improve.

US - Strong volume and revenue growth

· Fever-Tree delivered strong revenue growth of 22% during the year (24% at constant currency) despite the impact of a greater than expected FX headwind and a subdued macroeconomic environment in Q4.

· In the Off-Trade, Nielsen recorded sales increased by 24% year-on-year[3], driven by the strong performance of our new can format across all flavour categories.

· The brand had a very encouraging December and continues to perform ahead of the mixer category, extending our number one value share in both the Tonic and Ginger Beer categories3, with our innovation also performing strongly as we continue to broaden our category opportunity.

Europe - Brand continues to strengthen despite challenging trading backdrop

· Fever-Tree brand revenue grew by 6% (4% at constant currency) during the year. We continue to extend our premium mixer leadership position across Europe[4], but our revenue growth was impacted by subdued consumer sentiment in several markets, most notably in Germany. This meant our total revenue in Europe, including GDP portfolio brands in the German market, increased by 4% (2% at constant currency).

· We strengthened our route-to-market across the region and successfully completed the transition to new distributors in France and Greece during 2023, setting the brand up to take advantage of the significant category growth opportunities in these markets over the coming years.

Rest of the World - Building the platform for long-term growth

· Despite a positive second half performance, Fever-Tree's revenue declined by 14% for the full year (-10% at constant currency). Our revenue across the Rest of the World region excluding Australia was in growth, however, the transition to a new subsidiary set-up in Australia, which included a one-off inventory buy-back in the first half of the year, impacted revenue delivery for the total region.

· We remain the number one premium mixer in Australia[5] due to good underlying momentum of the brand and look forward to 2024 with optimism having set ourselves up to take advantage of this attractive market going forward.

· Fever-Tree also continues to make progress across our other Rest of the World markets, with exciting plans in Japan as we build on our relationship with Asahi Breweries.

FY24 outlook and guidance

· We expect to deliver good growth in 2024 and reiterate our guidance of 10% revenue growth for the Fever-Tree brand. We are refocusing our portfolio of non-Fever-Tree brands in Germany and, as such, expect c.£7 million reduction in portfolio brand revenue in 2024. As a result of this, we expect total Group revenue to grow by 8%.

· Importantly, we remain confident of delivering a significant improvement in gross margin in 2024, underpinned by new glass contracts with fully hedged energy pricing, lower Trans-Atlantic freight rates, a continuation of cost-saving initiatives, alongside our long-term approach to sustainable price increases across our markets. Therefore, we are also reiterating our guidance of c.15% Adjusted EBITDA margin for 2024.

Tim Warrillow, CEO of Fever-Tree commented:

"The Fever-Tree brand has performed well in 2023, growing our market share in all of our key markets, despite a challenging macroeconomic environment. The US ended the year as our largest region, where we have extended our leadership position in both the Tonic and Ginger Beer categories. The brand enjoyed a strong Christmas trading period in the UK, especially in the On-Trade, whilst at home, our new Espresso Martini mixer clearly became a festive drink of choice. Despite recession in Germany impacting our European performance and the one-off effect of the transition to our new subsidiary in Australia, we remain confident of driving good growth in those regions in 2024.

Importantly, we have driven a significant increase in our EBITDA margin in the second half of the year and are confident that the operational efficiencies we have implemented, alongside a reduction in inflationary cost pressures, will drive a doubling of EBITDA in 2024 and provide a strong platform for profitable growth going forward."

Fever-Tree will announce its Preliminary Results for the year ending 31st December 2023 on 26th March 2024.

For more information please contact:

Investor queries

Ann Hyams, Director of Investor Relations I ann.hyams@fever-tree.com I +44 (0)20 4516 8106

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024

 

Nominated Advisor and Broker - Investec Bank plc

David Flin I +44 (0)20 7597 5970

Corporate Broker - Morgan Stanley & Co. International plc

Andrew Foster I Jessica Pauley I +44 (0)20 7425 8000

Financial PR advisers - FGS Global

Faeth Birch +44 (0)7768 943 171; Anjali Unnikrishnan +44 (0)7826 534 233


[1] CGA

[2] CGA & IRI 2023

[3] US Nielsen 52 weeks to 30 Dec 2023

[4] Nielsen 52 weeks to 31 Dec 2023

[5] Woolworths & Coles scanner data

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUSAWRSNUAUAR
Date   Source Headline
27th Mar 20247:00 amRNSHolding(s) in Company
26th Mar 20247:00 amRNSFY23 Preliminary Results to 31 December 2023
25th Jan 202412:05 pmRNSDirector/PDMR Shareholding
25th Jan 20247:00 amRNSFY23 pre-close trading update
18th Jan 20242:30 pmRNSAdmission Application
18th Jan 20242:30 pmRNSBlock Admission Application
14th Dec 20232:33 pmRNSDirectorate Change
1st Dec 20237:00 amRNSBlock Listing Return
1st Dec 20237:00 amRNSTotal Voting Rights
1st Nov 20238:55 amRNSTotal Voting Rights
26th Oct 20233:25 pmRNSDirector/PDMR Shareholding
28th Sep 20236:20 pmRNSHolding(s) in Company
14th Sep 202312:18 pmRNSDirector/PDMR Shareholding
12th Sep 20236:25 pmRNSFever-Tree FY23 Interim Results - Replacement
12th Sep 20237:00 amRNSFever-Tree FY23 Interim Results
1st Aug 20232:16 pmRNSTotal Voting Rights
3rd Jul 20234:00 pmRNSTotal Voting Rights
1st Jun 20237:00 amRNSBlock Listing Return
1st Jun 20237:00 amRNSTotal Voting Rights
25th May 20231:54 pmRNSResult of AGM
25th May 20237:00 amRNSBoard Changes
25th May 20237:00 amRNSAGM Trading Statement
12th May 202311:25 amRNSHolding(s) in Company
5th May 20237:00 amRNSGrant of Options
2nd May 20237:00 amRNSTotal Voting Rights
21st Apr 20231:08 pmRNSNotice of AGM
22nd Mar 20237:00 amRNSFY22 Preliminary Results to 31 December 2022
8th Mar 20239:49 amRNSHolding(s) in Company
8th Feb 20232:56 pmRNSStandard form for notification of major holdings
30th Jan 20234:32 pmRNSHolding(s) in Company
26th Jan 20237:00 amRNSFY22 pre-close trading update
17th Jan 20239:45 amRNSStandard form for notification of major holdings
19th Dec 20227:00 amRNSBlock Admission Application
12th Dec 20227:00 amRNSDomenic De Lorenzo to succeed Bill Ronald as Chair
1st Dec 20229:00 amRNSBlock Listing Return
21st Nov 20227:00 amRNSChange Of Nominated Advisor and Corporate Broker
15th Nov 20226:18 pmRNSStandard form for notification of major holdings
1st Nov 20227:00 amRNSTotal Voting Rights
17th Oct 20223:09 pmRNSStandard form for notification of major holdings
4th Oct 202210:25 amRNSDirector/PDMR Shareholding
3rd Oct 20229:00 amRNSDirector/PDMR Shareholding
13th Sep 20227:00 amRNSFever-Tree FY22 Interim Results
1st Sep 20227:00 amRNSTotal Voting Rights
24th Aug 202212:06 pmRNSStandard form for notification of major holdings
19th Jul 20229:57 amRNSDirector/PDMR Shareholding
18th Jul 20227:00 amRNSDirector/PDMR Shareholding
15th Jul 20224:00 pmRNSDirector/PDMR Shareholding
15th Jul 202210:14 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSHY pre-close trading update
1st Jul 20222:26 pmRNSFever Tree drinks plc Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.